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Abstract
Background: Human papillomavirus (HPV) genotyping assays are becoming increasingly attractive for use in mass
screening, as they offer a possibility to integrate HPV screening with HPV vaccine monitoring, thereby generating
a synergy between the two main modes of cervical cancer prevention. The Genomica CLART HPV2 assay is a
semi-automated PCR-based microarray assay detecting 35 high-risk and low-risk HPV genotypes. However, few
reports have described this assay in cervical screening.
An aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in Copenhagen,
Denmark, an area with a high background risk of cervical cancer where women aged 23-65 years are targeted for
organized screening.
Methods: Material from 5,068 SurePath samples of women participating in routine screening and clinical follow-up
of cervical abnormalities was tested using liquid based cytology, CLART HPV2 and Hybrid Capture 2 (HC2).
Results: At least one of the 35 defined genotypes was detected by CLART in 1,896 (37%) samples. The most
frequent high-risk genotypes were HPV 16 (7%), HPV 52 (5%), and HPV 31 (4%). The most frequent low-risk genotypes
were HPV 53 (5%), HPV 61 (4%), and HPV 66 (3%). Among 4,793 women targeted by the screening program (23-65
years), 1,166 (24%) tested positive for one or more of the 13 high-risk genotypes. This proportion decreased from 40%
at age 23-29 years to 10% at age 60-65 years. On HC2, 1,035 (20%) samples were positive for any high-risk and thus
CLART showed a higher analytical sensitivity for 13 high-risk HPV genotypes than HC2, and this was found in all
age-groups and in women normal cytology.
Conclusions: CLART performed well with a positive reproducibility for high-risk genotypes of 86%, and a negative
reproducibility of 97%. This report furthermore updates the genotype distribution in Denmark prior to the inclusion of
the HPV-vaccinated cohorts into the screening program, and as such represents a valuable baseline for future vaccine
impact assessment.
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Background
Human Papillomavirus (HPV) infection is a necessary
cause of cervical cancer [1]. At present, 13 genotypes
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) are con-
sidered high-risk or probably high-risk [2]. Molecular assays
detecting DNA from these HPV genotypes, in particular
the commercially available Hybrid Capture 2 (HC2; Qiagen,
Hilden, Germany) and in-house polymerase chain reaction
(PCR) using GP5+/6+ primers, have been extensively
studied in randomized controlled trials. In these trials, a
high sensitivity for detection of high-grade cervical intrae-
pithelial neoplasia (CIN) was demonstrated for HPV testing
compared to cytology [3,4]. This makes molecular HPV
testing attractive for future cervical screening. Since 2006,
vaccination against genotypes 16 and 18 has been available,
primarily for younger birth cohorts. In Denmark, for
example, HPV vaccination has been recommended in
women under 26 years of age. The lower background
risk of cervical cancer expected in vaccinated women
is expected to reduce the positive predictive value of
cytology [5], reinforcing the case for a shift towards
HPV-based screening.
Several HPV assays are now commercially available.
The most frequently used assay, the Hybrid Capture 2
(HC2), detects a combination of 13 genotypes without
individual genotyping. However, inclusion of HPV16 and
18 in the present vaccines, and a higher number of geno-
types in next generation vaccines call for more detailed
monitoring of genotypes. For this purpose, HPV assays
with genotype resolution will be necessary. Commercially
available full-genotyping assays, e.g. Linear Array (Roche,
Rotkreuz, Switzerland) detecting 37 high- and low-risk
genotypes, or INNO-LiPA (Innogenetics, Gent, Belgium)
detecting 28 genotypes, have been extensively used in
research. However, their results are most often read
manually, and the tests are therefore prone to inter-
observer variability making quality assurance for use in
routine screening a challenge.
The CLART HPV2 (Genomica, Madrid, Spain) assay
offers an alternative for genotype specific screening cover-
ing 35 individual HPV genotypes, including all 13 high-
risk or probably high-risk genotypes. A set of primers to
amplify a fragment of the human CFTR gene (892 bp) is
included as a DNA control for sample adequacy, while
an additional set of primers to amplify a spiked plasmid
(1202 bp) is included as a PCR process control. The
resulting visualized microarray is analysed on a com-
puter guided reader with automated reading software.
This reduces inter-observer variation in reporting the
results, and is useful for high-throughput settings. Fur-
thermore, CLART is a versatile high-throughput assay
that can be applied to several sample types for HPV
diagnostics, including formalin fixed paraffin embedded
specimens [6-8]. Versatility and speed are becoming
increasingly crucial as laboratories, in supporting the cli-
nical diagnostic processes, undertake HPV testing on a
wide variety of sample types from the same patient.
Earlier studies reported mixed results when the detec-
tion of HPV and cervical lesions by CLART was com-
pared to that of HC2 [8-13]. All studies were undertaken
using samples stored in PreservCyt, and experts have
called for evaluation of HPV assays using other storage
media [14], e.g. SurePath. Here we present data from the
Horizon study comparing the outcomes of the CLART
and HC2 assays. The Horizon study is a split-sample,
population-based study of well-screened women with a
high background risk of cervical cancer [15,16], using
samples stored in SurePath. Moreover, the data presented
here will be the last population-based Danish data on
HPV prevalence in virtually unvaccinated women, and as




The Department of Pathology of Copenhagen University
Hospital in Hvidovre is the largest cervical screening la-
boratory in Denmark. While the study was on-going, it
annually evaluated 66,000 cervical SurePath samples
from women living in the municipalities of Copenhagen
and Frederiksberg (denoted as Copenhagen in the re-
mainder of the manuscript). The laboratory handles all
cervical cytology regardless of the reason for sample-
taking. Since the 1960’s, Copenhagen has been covered
by an organized cervical screening program. At present,
women aged 23-49 years are targeted for screening every
three years and women aged 50-65 years every five years.
In 2012, 75% of women had been screened at least once
within the recommended interval [17].
Sample collection
The Horizon study was nested into routine laboratory
practice. Upon arrival in the laboratory, SurePath sam-
ples were sequentially arranged into racks of 48. Samples
from the first one to four racks were collected for the
study, equally from Monday to Friday, between 10 June
and 25 August 2011. This collection method mimicked a
cohort of unselected consecutive liquid-based cytology
(LBC) samples, assuming that the time the sample ar-
rived in the laboratory was not associated with the
woman’s characteristics. Residual material was collected
after completion of routine LBC which included HC2
triage of women aged ≥30 years with atypical squamous
cells of undetermined significance (ASCUS). The volume
of the collected residual material was approximately
2 ml per sample, and it was diluted with 2 ml of Sure-
Path (dilution factor approximately 1:1) to obtain enough
volume for additional testing reported elsewhere [18-20].
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All testing was done in the same laboratory. In agreement
with the manufacturers, taking into account the additional
workload in this routine laboratory and the cost, the target
number of samples was 5,000.
Cytology
Cytological evaluation of SurePath samples was under-
taken by cytoscreeners, though in collaboration with a
pathologist in case of abnormal findings. Reading was
assisted by FocalPoint GS Imaging System (BD Diagnos-
tics, Burlington, NC, USA). The outcomes were reported
using the Bethesda 2001 system. They were classified as
negative for intraepithelial lesion or malignancy, ASCUS,
low-grade squamous intraepithelial lesions (LSIL), or
high-grade squamous intraepithelial lesions or worse
(≥HSIL) including atypical squamous cells - cannot ex-
clude HSIL (ASC-H), atypical glandular cells (AGC),
adenocarcinoma in situ (AIS), and squamous cell car-
cinoma. Cytoscreeners and pathologists were blinded to
the outcomes of HPV testing.
CLART HPV DNA testing
CLART HPV2 (Genomica, Madrid, Spain) is a low-
density microarray assay based on PCR amplification of
genotype specific HPV L1 fragments from 35 individual
HPV genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,
44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72,
73, 81, 82, 83, 84, 85 and 89), with analytical sensitivity
calibrated against known copies of cloned plasmids.
One ml of the diluted SurePath sample was spun
down (5 min, 14,000 revolutions per minute), with the
supernatant removed and cell pellet resuspended in a
mix of 180 μl phosphate buffered saline (10x conc.
pH 7.4, pharmacy product) and 20 μl Proteinase K (re-
combinant, PCR Grade, Roche Diagnostics). Samples
were then vortexed and incubated for one hour at 56°C
and one hour at 90°C. HPV DNA was purified using the
MagNa Pure LC 96 and MagNA Pure LC 32 instru-
ments with the MagNA Pure LC Total Nucleic Acid Iso-
lation Kit (all Roche Diagnostics, Rotkreutz, CH). Five μl
of purified DNA were used for the PCR amplification.
During amplification the PCR products were labeled
with biotin. Prior to visualization, the PCR products
were denatured at 95°C for 10 minutes. Visualization
was performed on the CLART microarray, using 10 μl of
the denatured PCR products. Hybridization between the
amplicons and their specific probes on CLART results
in formation of an insoluble precipitate of peroxidase
when adding a Streptavidin conjugate that bind to the
biotin-labeled PCR products. Precipitate is analyzed on
the Clinical Array Reader (Genomica, Madrid, Spain).
All samples returning an invalid outcome were retested,
and the second result was considered definitive.
Samples for evaluation of CLART’s intra-laboratory re-
producibility were collected, in part, within the Horizon
study. To obtain sufficient numbers of positive and
negative samples for the analysis, Horizon samples were
supplemented with other routine screening samples. Ex-
tracted DNA was used for this purpose, in order to
minimize any influence of the MagNA Pure step.
Hybrid capture 2 HPV DNA testing
HC2 is a hybridization assay detecting a combination of
13 high-risk genotypes, without an internal control for
sufficiency of sample material. SurePath samples were ei-
ther pretreated manually with DNA denatured prior to
testing according to the manufacturer’s protocol, or
DNA was isolated and purified using the DSP AXpH
DNA kit on the QIASymphony SP platform (Qiagen,
Hilden, Germany). Testing of these samples was per-
formed on automated Rapid Capture® System (Qiagen,
Gaithersburg, MD) using scripts depending on pretreat-
ment. A small number of samples from women with
ASCUS aged ≥30 years, in whom HPV triage was under-
taken routinely, were denatured and tested manually.
Processing of samples and assay instrumentation
The study protocol and assay testing protocols were
agreed upon with all manufacturers prior to the study.
All instrumentation and software were used as supplied
and maintained by the manufacturers.
Screening history
Women’s screening history from 1 January 2000 onwards
was retrieved from the Danish Pathology Data Bank [21],
where the reason for taking the sample has not been sys-
tematically registered. Horizon samples with an earlier
diagnosis of cervical cancer, a CIN diagnosis up to three
years earlier, ASCUS in the previous 15 months, or with
more severe cytological abnormalities or a positive HPV
test in the past 12 months were considered follow-up
samples. Horizon samples with no recent abnormality
were considered primary samples. The latter included
screening samples and a small proportion of samples
taken for indication.
Statistical analyses
CLART was assigned a positive result if it detected at
least one of the 13 high-risk HPV genotypes that are
included in HC2; HC2 if relative light unit to cut-off
(rlu/co) value was ≥1, and cytology when ≥ASCUS.
Differences in the distributions of age, screening his-
tory, cytology and HC2 outcomes between included and
excluded samples were tested with the χ2 test. Trends in
HPV positivity by age were tested with the Mantel-
Haenszel χ2 test for trend.
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Ethical considerations
Horizon was designed as a quality development study,
utilizing only residual material that would otherwise
have been discarded. According to Danish regulations of
biomedical research, published on 5 May 2011 in the
Guidelines about Notification etc. of a Biomedical Re-
search Project to the Committee System on Biomedical
Research Ethics No. 9154 section 2.5, quality develop-
ment studies do not require ethical approval. The study
was notified to the Danish Data Protection Agency in
concordance with the current guidelines (The Act on




Of the 12,138 consecutive samples received in the labora-
tory during the collection period, 6,258 (52%) were se-
lected for the study. All selected samples were tested with
HC2 except 23 (0.4%), and with LBC. In total, 1,190 (19%)
samples were not tested with CLART owing to insufficient
residual volume (n = 1,165) or to human error (n = 25),
and were excluded. Excluded samples were not signifi-
cantly different from the remaining 5,068 samples in
terms of age (P = 0.09), cytology (P = 0.55), and HC2
outcome (P = 0.31). There was a small statistically sig-
nificant difference in the women’s screening history,
with 13% of the included and 10% of the excluded sam-
ples being follow-up samples (P = 0.01). Five thousand
and nine women contributed one sample (99% of all
samples), 28 contributed two, and one woman three
samples. The mean age of the women was 37.3 years
(SD = 12.3, range: 16-89). The mean number of days
between the receipt of the sample in the laboratory and
storing was 2 (range: 1-5).
Genotype frequency, and single versus multiple infections
At least one of 35 genotypes was detected by CLART in
1,896 (37%) samples (Table 1). The most frequent high-
risk genotypes were HPV 16 (n = 346, 7%), HPV 52
(n = 247, 5%), and HPV 31 (n = 218, 4%, Figure 1). Of
all 1,274 (25%) samples with high-risk genotypes, 496
(39%) were single infections. The most frequent low-risk
genotypes were HPV 53 (n = 262, 5%), HPV 61 (n = 186,
4%), and HPV 66 (n = 157, 3%). From 1,207 samples with
infections with low-risk genotypes, 492 (41%) were single
infections, and 622 (52%) were purely low risk infections
with no detected HR-genotypes in the sample.
Among 4,793 women targeted by the screening pro-
gram (23-65 years), 1,166 (24%) tested positive for
high-risk genotypes (Table 2). This proportion decreased
from 40% at age 23-29 years to 10% at age 60-65 years
(P < 0.0001). Infections with only low-risk genotypes
showed a small but significant decrease by age (P = 0.03).
In women aged 16-22 and >65 years, 61% and 8%, respect-
ively, tested positive on high-risk genotypes. These women
are not routinely invited for screening, but may have
presented for medical conditions, sought screening
themselves, or were tested for follow-up of an earlier
abnormality.
Concurrent cytology
Cytological abnormalities were detected in 371 (7%) of
samples. The proportion of CLART positive samples in-
creased by cytological grade; 1,001 (21%) samples with
normal cytology were positive on CLART; 72 (59%) with
ASCUS; 103 (73%) with LSIL; and 97 (92%) with ≥HSIL
(P < 0.0001). The small proportion of samples with only
low-risk genotypes showed no trend by cytological grade
(P = 0.28). Among women aged 23-65 years, HPV 16
was found in 235 (5%), and HPV 18 in 88 (2%) of 4,435
samples with normal cytology (Table 3). Furthermore,
HPV 16 was found in 16 (14%) of ASCUS; 27 (21%) of
LSIL; and 37 (38%) of ≥HSIL samples; whereas HPV 18
was found in 7 (6%) of ASCUS; 7 (5%) of LSIL; and 15
(16%) of ≥HSIL samples. Among cytology normal sam-
ples at this age, at least one high-risk genotype was de-
tected in 923 (21%), whereas this was the case in 242
(72%) of cytology abnormal samples. Multiple infections
with high-risk genotypes were more frequent than single
infections regardless of the grade of cytological abnor-
mality. Infections with only low-risk genotypes were de-
tected in 530 (12%) cytology normal, and in 53 (16%)
cytology abnormal samples.
CLART versus HC2
CLART could be compared to HC2 on 5,064 samples, as
four samples were not tested with HC2. Here, 1,035
(20%) samples were positive on HC2, HC2 being positive
in 874 (69%) CLART-positive samples, and in 160 (4%)
CLART-negative samples. The majority, 111 (69%), of
CLART-negative/HC2 positive samples tested positive
on CLART low-risk genotypes, indicating some HC2
cross-reactivity to low-risk HPV genotypes. HC2 showed
slightly lower prevalence of high-risk HPV infections
than CLART in all age groups; the prevalence decreased
from 57% (92/162) at age 16-22 years, to 33% (507/
1,534) at age 23-29 years, 17% (266/1,525) at age 30-39
years, 11% (112/991) at age 40-49 years, 7% (37/506) at
age 50–59 years, 6% (14/234) at age 60-65 years, and 6%
(7/112) at age >65 years. Compared to CLART, HC2
tested positive in fewer samples with normal cytology,
16% (728/4,667), but in more samples with low-grade
abnormal cytology, 64% (79/123) in ASCUS, and 90%
(128/142) in LSIL. Both assays tested positive on 92%
(97/106) of samples diagnosed as ≥HSIL; on 94 of these
97 samples both CLART and HC2 returned a positive
result, whereas three samples tested positive on CLART
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and negative on HC2, and additional three samples
tested negative on CLART and positive on HC2.
Outcome in primary screening samples
When only the 4,410 primary screening samples without
a recent abnormality were considered, 1,024 (23%) tested
positive on CLART; 822 (19%) on HC2; and 241 (5%)
had ≥ASCUS (Table 4). Among the 23-29 year olds, 7%
had ≥ASCUS, and among 30-65 year olds that was the
case in a relatively stable proportion of 4% (Figure 2).
On the other hand, the proportion of women with a
positive CLART test and normal cytology was strongly
age-dependent, and it decreased from 31% (400/1,287)
at age 23-29 years, to 18% (228/1,299) at 30-39 years,
11% (96/904) at 40-49 years, 8% (37/465) at age 50-59
years, and 8% (17/215) at age 60-65 years (P < 0.0001).
Intra-laboratory reproducibility of CLART
Out of 273 samples collected for evaluation of reprodu-
cibility, showing no high-risk or low-risk genotypes in
the first run, 256 (94%) could be reproduced. Among
the 17 (6%) non-reproducible samples, 8 showed high-
risk infections in the second run. Hence, when only
high-risk infections were considered as a positive result
in the second run, the negative reproducibility was 97%
(264/273).
Among the 371 samples in which at least one of the
35 HPV genotypes was detected by CLART in the first
run, 329 (89%) still had at least one genotype detectable
in the second run. No genotype was detected in the sec-
ond run among the remaining 42 (11%) samples, of
which 28 initially showed infections with at least one
high-risk genotype. Restricting the evaluation to the 283
samples with high-risk genotypes detected in the first
run, 243 (86%) reproduced a high-risk genotype. An
HPV 16 result from the first run (n = 71) was repro-
duced in 67 (94%) samples, and for HPV 18 (n = 30) this
was the case in 25 (83%) samples.
Assuming that in routine work, 25% had high-risk HPV
on CLART (Table 2), 94% (= (25% × 86%) + (75% × 97%))
of all samples would have a reproducible result. For
women with screening samples at age 30-65 years, 16%
tested positive on CLART (Table 3), and 95% (= (16% ×
86%) + (84% × 97%)) would be reproducible.
Discussion
The Horizon study is the first population-based study to
quantify cervical HPV infections using CLART HPV2
genotyping assay with cross comparison to HC2 on un-
selected screening samples stored in SurePath. Denmark
has a high-risk, but well screened, population with re-
spect to cervical cancer, and CLART detected at least
one high-risk genotype in 25% of the samples, compared
to 20% by HC2. The proportion testing positive decreased
Table 1 Distribution of infections in the 5,068 samples,
by HPV genotype as detected by CLART
Infections
HPV genotypes Single (%) Multiple (%) Total (%)
High-riska
16 120 (35%) 226 (65%) 346 (100%)
18 31 (24%) 97 (76%) 128 (100%)
31 44 (20%) 174 (80%) 218 (100%)
33 35 (25%) 107 (75%) 142 (100%)
35 18 (22%) 64 (78%) 82 (100%)
39 17 (25%) 50 (75%) 67 (100%)
45 14 (18%) 62 (82%) 76 (100%)
51 41 (22%) 143 (78%) 184 (100%)
52 79 (32%) 168 (68%) 247 (100%)
56 18 (19%) 78 (81%) 96 (100%)
58 45 (24%) 139 (76%) 184 (100%)
59 31 (23%) 103 (77%) 134 (100%)
68 3 (3%) 100 (97%) 103 (100%)
≥1 high-risk genotype 496 (39%) 778 (61%) 1,274 (100%)
≥1 high-risk genotype,
no low-risk genotype
496 (72%) 193 (28%) 689 (100%)
Low-riska
6 34 (28%) 86 (72%) 120 (100%)
11 4 (33%) 8 (67%) 12 (100%)
26 2 (15%) 11 (85%) 13 (100%)
40 1 (6%) 16 (94%) 17 (100%)
42 20 (24%) 64 (76%) 84 (100%)
43 0 0 0
44 5 (12%) 37 (88%) 42 (100%)
53 69 (26%) 193 (74%) 262 (100%)
54 20 (28%) 51 (72%) 71 (100%)
61 58 (31%) 128 (69%) 186 (100%)
62 36 (32%) 75 (68%) 111 (100%)
66 52 (33%) 105 (67%) 157 (100%)
70 55 (37%) 94 (63%) 149 (100%)
71 4 (36%) 7 (64%) 11 (100%)
72 10 (40%) 15 (60%) 25 (100%)
73 5 (20%) 20 (80%) 25 (100%)
81 27 (28%) 68 (72%) 95 (100%)
82 20 (14%) 121 (86%) 141 (100%)
83 45 (41%) 64 (59%) 109 (100%)
84 25 (28%) 64 (72%) 89 (100%)
85 0 0 0
89 0 0 0
≥1 low-risk genotype 492 (41%) 715 (59%) 1,207 (100%)
≥1 low-risk genotype,
no high-risk genotype
492 (79%) 130 (21%) 622 (100%)
≥1 high-risk or low-risk
genotype
988 (52%) 908 (48%) 1,896 (100%)
Abbreviations: HPV Human Papillomavirus.
aAccording to the classification reported by IARC [2].
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strongly with women’s age. In primary screening of
women aged ≥30 years, 16% tested positive on CLART,
and 12% on HC2; and most of these women had normal
cytology. HPV 16 causing more than half of cervical
cancers [22], was found in 7% of women. Additionally, 12%
of women were infected with only low-risk genotypes.
We also evaluated CLART’s laboratory performance.
Here, focus was on intra-laboratory reproducibility, as a
lack thereof may pose problems for laboratories, e.g. in
terms of their ability to verify the initial findings. In total,
94% of samples initially negative on all 35 genotypes were
negative at retesting. When only high-risk genotypes were
considered, this was 97%. Similarly, 89% of samples ini-
tially testing positive for at least one of the 35 genotypes,
were positive at retesting. When only high-risk genotypes
were considered, this was 86%. Taking the proportions of
HPV positive and negative samples into account, overall
94% of samples were reproducible. This was similar to the
reproducibility evaluated in the Horizon study of two
other newly available commercial assays, Roche’s cobas
[19] and Hologic/Gen-Probe’s APTIMA [18]. In a small
Portuguese study of CLART (n = 75), 99% of archived
ThinPrep samples were reproducible [12]. The proportion
of positive samples was not reported from that study. We
conclude that by using an approach including a pre-
warming step to counter any cross linking effect on a
sample’s genomic material by SurePath, CLART was
reproducible. This protocol modification was agreed upon
with the manufacturer prior to the study. The differences
to previous findings on ThinPrep appear relatively small,
though SurePath due to its formaldehyde content poses a
larger challenge to molecular HPV assays than the metha-
nol based ThinPrep.
We had to exclude 19% of the samples owing to insuffi-
cient volume of available residual material. However, there
was no significant difference between the included and the
excluded samples in terms of the women’s age, cytology,
and the HC2 outcome. All samples were tested in one la-
boratory by the same staff, and the instrumentation was
used as supplied and maintained by the manufacturers. Al-
though there may be some differences between automated
and manual DNA extraction, we used the former method
in our study. This allowed us to evaluate CLART in a rela-
tively high throughput fashion. This is important as manual
extraction in a laboratory routinely running >10,000 HPV
tests per year would be feasible neither from a patient safety
nor from a quality control/quality assurance point of view.
Although SurePath is a widely used screening medium for
sample collection, no previous study has addressed the use
of CLART technology for HPV detection on this media
type, using automated extraction and testing.
In 2004-2005, a total of 11,617 consecutive (screening)
SurePath samples evaluated in the same laboratory were
tested with HC2 [15]. The median age of the women in
that study was 36.4 years (range: 15-93), and 6% had ab-
normal cytology. The proportion of women aged 25-64
years testing positive on HC2 was ~17%, which is similar
to 16% in Horizon. Horizon results are therefore in good
agreement with the earlier data from the same population.
So far CLART’s clinical performance has only been
evaluated in a handful of studies, and several of these
did not compare with that of HC2 [8,13,23-26]. In 405
Portuguese women aged 25-63 years attending colposcopy
for cervical abnormalities, 268 (63%) tested positive on
CLART (13 high-risk genotypes), and 274 (64%) tested
positive on HC2. In total, 99% of the samples were
concordant between CLART and HC2. The sensitivity
for ≥ CIN2 of both assays was 96% (95% CI: 93-98),
and the specificities were comparable, 74% (95% CI:
67-80) for CLART, and 71% (95% CI: 64-78) for HC2
[12]. In a UK study including 953 women referred for
colposcopy after cytological abnormalities, the sensitivity
Figure 1 Genotype distribution on 5,068 unselected samples tested on CLART.
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of CLART for ≥CIN3, 84% (95% CI: 77-89), was lower
than that of HC2, 99% (95% CI: 97-100). CLART’s specifi-
city was higher than that of HC2, 36% (95% CI: 32-40) vs.
25% (95% CI: 22-29), respectively [9]. The authors though
mentioned technical problems in evaluation of CLART,
and suggested caution in interpreting these results. In the
Horizon study, the histological follow-up of women with
positive screening tests is underway. Following routine
recommendations in Denmark, women with abnormal
cytology were offered additional testing. In addition, we
invited women with normal cytology and at least one
positive HPV test for repeated testing after 18 months.
Standard measures of sensitivity and specificity will be
reported once follow-up data are available.
Experts largely discourage use of HPV DNA testing in
routine screening of women below age 30 years [27]. In
our study, 38% of screening samples from women aged
23-29 years tested positive on CLART, and 33% on HC2.
In comparison, HPV DNA testing in women aged 30-65
years showed that 16% of screened women tested positive
on CLART, 12% on HC2, and 4.4% on LBC (Figure 2). Re-
cent data for Copenhagen, retrieved from the national
Pathology Data Bank, showed that 1.3% of screened
women had ≥CIN3 detected following abnormal cytology.
If HPV testing is 32% more sensitive for ≥CIN3 than
cytology [28], about 1.7% of women are expected to have ≥
CIN3 detected after a positive HPV test. Thus, 14.0%
(=15.7-1.7) of women aged 30-65 years are expected to
get a false-positive CLART test, defined as a positive
CLART test without a subsequent diagnosis of ≥ CIN3.
On HC2, 10.0% (=11.7-1.7) had a false-positive test, and
3.1% (=4.4-1.3) on LBC. The lifetime background risk of
cervical cancer in Danish women is estimated at <4%
[29]. Hence, the very high proportions of women with
false-positive HPV tests, on CLART and HC2 alike, per
screening round represent a challenge for the imple-
mentation of primary HPV screening in women above
the age of 30 years.
Table 2 CLART results for 5,068 samples, by age, screening history, cytology, and HC2 results
Outcomes on CLART, N (%)
Any high-risk HPV
genotype (%)a




Invalid (%) Total (%)
Total 1,274 (25.1%) 3,782 (74.6%) 622 (12.3%) 12 (0.2%) 5,068 (100%)
Age (years)
16-22 99 (61.1%) 63 (38.9%) 20 (12.3%) 0 (0.0%) 162 (100%)
23-29 608 (39.6%) 926 (60.3%) 216 (14.1%) 1 (0.1%) 1,535 (100%)
30-39 345 (22.6%) 1,176 (77.1%) 171 (11.2%) 4 (0.3%) 1,525 (100%)
40-49 135 (13.6%) 851 (85.8%) 119 (12.0%) 6 (0.6%) 992 (100%)
50-59 54 (10.7%) 452 (89.2%) 55 (10.8%) 1 (0.2%) 507 (100%)
60-65 24 (10.3%) 210 (89.7%) 25 (10.7%) 0 (0.0%) 234 (100%)
>65 9 (8.0%) 104 (92.0%) 16 (14.2%) 0 (0.0%) 113 (100%)
Screening history
Primary samplec 1,024 (23.2%) 3,375 (76.5%) 528 (12.0%) 11 (0.2%) 4,410 (100%)
Follow-up sample 250 (38.0%) 407 (61.9%) 94 (14.3%) 1 (0.2%) 658 (100%)
Cytology
Normal 1,001 (21.4%) 3,658 (78.3%) 561 (12.0%) 12 (0.3%) 4,671 (100%)
ASCUS 72 (58.5%) 51 (41.5%) 18 (14.6%) 0 (0.0%) 123 (100%)
LSIL 103 (72.5%) 39 (27.5%) 35 (24.6%) 0 (0.0%) 142 (100%)
≥HSIL 97 (91.5%) 9 (8.5%) 5 (4.7%) 0 (0.0%) 106 (100%)
≥ASCUS 272 (73.3%) 99 (26.7%) 58 (15.6%) 0 (0.0%) 371 (100%)
Inadequate 1 (3.8%) 25 (96.2%) 3 (11.5%) 0 (0.0%) 26 (100%)
HC2d
Positive 874 (84.4%) 160 (15.5%) 111 (10.7%) 1 (0.1%) 1,035 (100%)
Negative 399 (9.9%) 3,619 (89.8%) 510 (12.7%) 11 (0.3%) 4,029 (100%)
Abbreviations: ASCUS atypical squamous cells of undetermined significance, HC2Hybrid Capture 2 assay, HPVHuman Papillomavirus, ≥HSIL high-grade intraepithelial
lesions or worse, LSIL low-grade squamous intraepithelial lesions.
aThirteen high-risk and probably high-risk genotypes, according to the classification reported by IARC [2].
bNone of the 13 high-risk or probably high-risk genotypes detected.
cPredominantly screening samples, including a small proportion of samples taken for indication.
dFour samples were not tested with HC2.
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Several marketed HPV assays have partial or full geno-
typing. The added value for screening of detailed geno-
typing is widely debated, yet it has been suggested to use
genotyping in triage of HPV-positive women to colpos-
copy [30]. However, from a screening perspective, the
main advantage of HPV genotyping would be to reduce
the number of false-positive tests sometimes seen with
cross-reactivity between high-risk probes/primers and
low-risk genotypes. In our study, this was exemplified by
160 samples (3% of all samples) positive on HC2 but
negative on high-risk CLART genotypes, of which 111
(2% of all samples) tested positive on low-risk CLART ge-
notypes. Moreover, HPV 66, a genotype with limited evi-
dence for carcinogenicity (group 2B carcinogen) [2], and
detectable by e.g. cobas, Abbott RealTime HPV test, BD
Onclarity and APTIMA, was found in 3% (157/5,068;
Table 1) of our samples; and in about half of these samples
(72/157), no high-risk genotype was detected. This raises
a question on whether inclusion of HPV 66 in non-
genotyping assays may result in unnecessary follow-up
and referrals for colposcopy. In 8% of all samples, CLART
detected high-risk genotypes whereas HC2 returned a
negative result (Table 2), probably due to the difference in
HPV detection technology, CLART being a PCR-based
assay and HC2 a hybridization assay. The significance of
these discordant tests will be explored when follow-up
data are available.
In monitoring the effect of HPV vaccination, the use
of genotyping assays will be very important. HPV vaccin-
ation is expected to change the dynamics of the screen-
ing programs by decreasing the background incidence of
cervical cancer and hence also the need for treatment of
CIN [31]. Until now, however, only a few countries have
implemented organised monitoring of vaccine impact.
Using genotyping assays, the task of screening and vaccine
monitoring could be combined, lowering the overall costs.
For this to become a reality, however, it will be necessary
to firmly establish that the genotyping assays perform
equally well on both sensitivity and specificity as the cur-
rently widely used non-genotyping assays like HC2.
Conclusions
In summary, this is the first investigation of performance
of the CLART HPV2 genotyping assay in a population-
Table 3 Prevalence of high-risk and low-risk HPV genotypes as detected by the CLART assay in women aged 23–65
years, by cytology
Cytology result
HPV genotype Normal (N = 4,435) ASCUS (N = 110) LSIL (N = 129) ≥HSIL (N = 96) ≥ASCUS (N = 335)
HPV 16 235 (5.3%) 16 (14.5%) 27 (20.9%) 37 (38.5%) 80 (23.9%)
HPV 18 88 (2.0%) 7 (6.4%) 7 (5.4%) 15 (15.6%) 29 (8.7%)
HPV 31 157 (3.5%) 8 (7.3%) 20 (15.5%) 16 (16.7%) 44 (13.1%)
HPV 33 98 (2.2%) 6 (5.5%) 13 (10.1%) 8 (8.3%) 27 (8.1%)
HPV 35 52 (1.2%) 8 (7.3%) 6 (4.7%) 3 (3.1%) 17 (5.1%)
HPV 39 38 (0.9%) 5 (4.5%) 15 (11.6%) 2 (2.1%) 22 (6.6%)
HPV 45 43 (1.0%) 8 (7.3%) 9 (7.0%) 9 (9.4%) 26 (7.8%)
HPV 51 139 (3.1%) 8 (7.3%) 10 (7.8%) 6 (6.3%) 24 (7.2%)
HPV 52 171 (3.9%) 14 (12.7%) 12 (9.3%) 24 (25.0%) 50 (14.9%)
HPV 56 52 (1.2%) 6 (5.5%) 24 (18.6%) 1 (1.0%) 31 (9.3%)
HPV 58 133 (3.0%) 12 (10.9%) 12 (9.3%) 10 (10.4%) 34 (10.1%)
HPV 59 90 (2.0%) 8 (7.3%) 13 (10.1%) 5 (5.2%) 26 (7.8%)
HPV 66 115 (2.6%) 5 (4.5%) 22 (17.1%) 2 (2.1%) 29 (8.7%)
HPV 68 68 (1.5%) 4 (3.6%) 14 (10.9%) 8 (8.3%) 26 (7.8%)
≥1 high-risk genotypea 923 (20.8%) 61 (55.5%) 93 (72.1%) 88 (91.7%) 242 (72.2%)
Single infection with a high-risk genotypea 388 (8.7%) 22 (20.0%) 20 (15.5%) 37 (38.5%) 79 (23.6%)
Multiple infection including high-risk genotype(s)a 535 (12.1%) 39 (35.5%) 73 (56.6%) 51 (53.1%) 163 (48.7%)
≥1 low-risk genotypea 943 (21.3%) 40 (36.4%) 88 (68.2%) 34 (35.4%) 162 (48.4%)
≥1 low-risk genotype, no high-risk genotypea 530 (12.0%) 17 (15.5%) 32 (24.8%) 4 (4.2%) 53 (15.8%)
No high- or low-risk genotype 2,970 (67.0%) 32 (29.1%) 4 (3.1%) 4 (4.2%) 40 (11.9%)
Abbreviations: ASCUS atypical squamous cells of undetermined significance, HC2Hybrid Capture 2 assay, HPVHuman Papillomavirus, ≥HSIL high-grade intraepithelial
lesions or worse, LSIL low-grade squamous intraepithelial lesions.
aCategorization of HPV genotypes into high-risk and low-risk groups followed IARC’s classification [2], according to which genotype 66 is considered “possibly
carcinogenic” (low-risk).
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Table 4 CLART results for 4,410 primarya samples, by age, screening history, cytology, and HC2 results
Outcomes on CLART, N (%)
Any high-risk genotype (%)b No high-risk genotypes (%)c Only low-risk genotypes (%)b Invalid (%) Total (%)
Total 1,024 (23.2%) 3,375 (76.5%) 528 (12.0%) 11 (0.2%) 4,410 (100%)
Age (years)
16-22 77 (57.0%) 58 (43.0%) 18 (13.3%) 0 (0.0%) 135 (100%)
23-29 485 (37.7%) 801 (62.2%) 175 (13.6%) 1 (0.1%) 1,287 (100%)
30-39 274 (21.1%) 1,021 (78.6%) 139 (10.7%) 4 (0.3%) 1,299 (100%)
40-49 116 (12.8%) 783 (86.6%) 104 (11.5%) 5 (0.6%) 904 (100%)
50-59 45 (9.7%) 419 (90.1%) 55 (11.8%) 1 (0.2%) 465 (100%)
60-65 19 (8.8%) 196 (91.2%) 22 (10.2%) 0 (0.0%) 215 (100%)
>65 8 (7.6%) 97 (92.4%) 15 (14.3%) 0 (0.0%) 105 (100%)
Cytology
Normal 847 (20.4%) 3,290 (79.3%) 494 (11.9%) 11 (0.3%) 4,148 (100%)
ASCUS 49 (57.6%) 36 (42.4%) 9 (10.6%) 0 (0.0%) 85 (100%)
LSIL 64 (73.6%) 23 (26.4%) 20 (23.0%) 0 (0.0%) 87 (100%)
≥HSIL 64 (92.8%) 5 (7.2%) 2 (2.9%) 0 (0.0%) 69 (100%)
≥ASCUS 177 (73.4%) 64 (26.6%) 31 (12.9%) 0 (0.0%) 241 (100%)
Inadequate 0 (0.0%) 21 (100%) 3 (14.3%) 0 (0.0%) 21 (100%)
HC2d
Positive 693 (84.3%) 128 (15.6%) 84 (10.2%) 1 (0.1%) 822 (100%)
Negative 330 (9.2%) 3,245 (90.5%) 444 (12.4%) 10 (0.3%) 3,585 (100%)
Abbreviations: ASCUS atypical squamous cells of undetermined significance, HC2Hybrid Capture 2 assay, HPVHuman Papillomavirus, ≥HSIL high-grade intraepithelial
lesions or worse, LSIL low-grade squamous intraepithelial lesions.
aPredominantly screening samples, including a small proportion of samples taken for indication.
bAccording to classification reported by IARC [2].
cConsidered negative on the CLART assay.
dThree samples were not tested with HC2.
Figure 2 Proportions of the 4,410 screening samples testing positive on CLART, and with abnormal cytology, by age.
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based study using unselected screening samples col-
lected in SurePath. CLART performed well with positive
and negative reproducibility comparable to that of other
commercially available assays. Moreover, CLART showed
a higher positivity rate for 13 high-risk HPV genotypes
than HC2. As HPV-vaccinated birth cohorts are soon
to enter screening age, our study maps the last pre-
vaccination HPV genotype distribution in Danish women,
and can as such serve as reference for the monitoring
vaccine impact.
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